Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1

Interventions

Rituximab 30acalabrutinib 15ibrutinib 13Cyclophosphamide 13Lenalidomide 12CT-P10 12zanubrutinib 9venetoclax 9Magnetic Resonance Spectroscopy 9Specimen Handling 8obinutuzumab 7Cytarabine 7Biopsy 7Bendamustine Hydrochloride 7pirtobrutinib 6glofitamab 6fludarabine 6fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Cyclosporine 5brexucabtagene autoleucel 4Whole-Body Irradiation 4Vincristine 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4Stem Cell Transplantation 3Sirolimus 3Methotrexate 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × loncastuximab tesirine × 90 days × Clear all
NCT05453396 2026-05-11

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

University of Washington

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡